https://hdl.handle.net/2072/451666 Mon, 06 Apr 2026 23:29:20 GMT 2026-04-06T23:29:20Z https://hdl.handle.net/11351/14400 Factors that affect distance-corrected near visual acuity in partial range of focus intraocular lenses López, Elena; Rodríguez, Lara; Martín, Cristina; Insa, Bea; Goñi, Idoia; Krolo, Iva; Guarro, Merce; Biarnés, Marc Aberrations; Extended depth-of-focus intraocular lenses; Near visual acuity; Aberraciones; Lentes intraoculares de profundidad de campo extendida; Agudeza visual cercana; Aberracions; Lents intraoculars amb profunditat de focus ampliada; Agudesa visual propera; Partial range of focus (ROF) intraocular lenses (IOL) offer excellent distance and intermediate visual acuity, but usually limited distance-corrected near visual acuity (DCNVA). We evaluated the characteristics of eyes implanted with two specific ROF IOL and very good DCNVA. We conducted a prospective, observational, cross-sectional study. Patients implanted with a ROF IOL were visited 1-3 months after uneventful phacoemulsification. We determined mono/binocular, corrected/uncorrected visual acuities (VA) at far, intermediate and near distance; photopic pupil diameter, corneal asphericity, aberrations (RMSHOA, Z4- 0), and axial length (Pentacam® AXL Wave; Oculus, Germany); and implanted IOL power. Monocular DCNVA was stratified in tertiles, with eyes in the first (better DCNVA) compared to the others (standard DCNVA). Univariate and multivariate generalized estimating equations models were used to compare the features of both groups. One-hundred eyes from 50 patients (mean age 69.0 years [SD 8.7], 66.0% female) were enrolled. Monocular distance logMAR VA was 0.00 (0.04) and DCNVA was 0.37 (0.15). Only younger age (66.4 vs. 71.0 years), smaller pupil (2.81 vs. 3.04 mm), and better distance VA (0.00 vs. 0.02 logMAR) were associated with better DCNVA. Therefore, a better distance-corrected VA, smaller photopic pupil diameter and younger age favored better DCNVA with the tested ROF IOL. Fri, 27 Mar 2026 08:29:46 GMT https://hdl.handle.net/11351/14400 2026-03-27T08:29:46Z https://hdl.handle.net/11351/14241 Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry Hernández Cruz, Blanca; Otero Varela, Lucía; Freire-González, Mercedes; GARCIA-GONZALEZ, JAVIER; Busquets Pérez, Noemi; moreno ramos, manuel josé Chronic inflammatory diseases; Janus kinase inhibitors; Tumour necrosis factor inhibitors; Enfermedades inflamatorias crónicas; Inhibidores de la cinasa Janus; Inhibidores del factor de necrosis tumoral; Malalties inflamatòries cròniques; Inhibidors de la Janus quinasa; Inhibidors del factor de necrosi tumoral; Objectives: To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Methods: We analysed data from patients included in BIOBADASER 3.0 and treated with JAKi or TNFi from 2015 to 2023 and estimated the incidence rate ratio (IRR) of adverse events and persistence. Results: A total of 6826 patients were included. Of these, 52% had RA, 25% psoriatic arthritis and 23% axial SpA. Treatment was with TNFi in 86%. The mean duration of treatment was 2.2±2.0 years with TNFi versus 1.8±1.5 with JAKi. JAKis were prescribed in older patients with longer term disease, greater comorbidity and later treatment lines and more frequently as monotherapy. The IRR of all infections and gastrointestinal events was higher among patients with RA treated with JAKi. Drug persistence at 1, 2 and 3 years was 69%, 55% and 45% for TNFi and 68%, 54% and 45% for JAKi. Multivariate regression models showed a lower probability of discontinuation for JAKi (HR=0.85; 95% CI 0.78-0.92) and concomitant conventional synthetic disease-modifying antirheumatic drugs (HR=0.90; 95% CI 0.84-0.96). The risk of discontinuation increased with glucocorticoids, comorbidities, greater disease activity and later treatment lines. Conclusions: Infections, herpes zoster and gastrointestinal adverse events in patients with RA tended to be more frequent with JAKi. However, prognosis was poor in patients receiving JAKi. Persistence was similar for TNFi and JAKi, although factors associated with discontinuation differed by diagnostic group. Thu, 12 Feb 2026 11:25:26 GMT https://hdl.handle.net/11351/14241 2026-02-12T11:25:26Z https://hdl.handle.net/11351/14244 Lepromatous Leprosy in an Immunosuppressed Patient Due to Renal Transplantation Associated with Glucose-6-Phosphate Dehydrogenase Deficiency: A Diagnostic and Therapeutic Challenge Fernández-Vela, Javier; Romaní, Jorge; Martin-Ezquerra, Gemma Lepromatous Leprosy; Renal Transplantation; Immunosuppressed Patient; Lepra lepromatosa; Trasplante renal; Paciente inmunodeprimido; Lepra lepromatosa; Trasplantament renal; Pacient immunosupressor; Leprosy, declared “eliminated” by WHO in 2000, persists globally with 165,459 cases recorded in 2022.[1] Leprosy in solid organ transplant recipients remains rare, with a few documented examples.[2,3] This case report explores the complex challenges in diagnosing and treating leprosy in solid organ transplantation, characterized by intricate polypharmacological treatments and immunomodulatory drugs. A 56-year-old male, originally from Senegal but residing in Spain since 1996, presented to the dermatology department in november 2022 with multiple elastic nodules on his upper extremities and face [Figure 1]. These lesions persisted for two months without accompanying symptoms or loss of thermosensory sensitivity. The patient had a kidney transplant in 2014 due to interstitial nephropathy, necessitating ongoing immunosuppression with tacrolimus and sirolimus. Thu, 12 Feb 2026 12:13:45 GMT https://hdl.handle.net/11351/14244 2026-02-12T12:13:45Z https://hdl.handle.net/11351/14242 Longitudinal study for the early detection of autism in children with very preterm birth Gisbert Gustemps, Laura; Martínez-Maldonado, Sergi; Coronado Contreras, Ricard; Marín Soro, Marta; Boix, Hector Trastorno del espectro autista; Diagnóstico temprano; Bajo peso al nacer; Autism spectrum disorder; Early diagnosis; Low birth weight; Trastorn de l'espectre autista; Diagnòstic precoç; Baix pes en néixer; Introduction: Very preterm birth is an important risk factor for autism spectrum disorder (ASD). The aim of this study is the early detection of ASD risk, using a follow-up protocol, in children weighing less than 1500 g at birth or born before 32 weeks of gestation. Methods: This is a prospective longitudinal study in which a total of 133 very premature babies were monitored to the age of 2 years with the M-CHAT autism screening test and, in the event of a positive result, the Autism Diagnostic Observation Schedule (ADOS-2). Results: 53 cases (4 out of 10) screened positive, and the rest negative. Among the positives, the ADOS-2 was administered in 50 cases, of which 24 scored above the ASD cutoff point. The average age of detection was 25.39 months. The results suggest an estimated prevalence of ASD in the very premature population of 18.46 %. Conclusions: The application of the follow-up protocol in the very premature population is effective for early detection of ASD. Thu, 12 Feb 2026 11:41:11 GMT https://hdl.handle.net/11351/14242 2026-02-12T11:41:11Z